
Next-Generation Vaccines
At the Christopher Anderson Laboratory, we’re building the future of vaccines with a particular focus on protecting the most vulnerable, infants at risk of severe respiratory infections. Our primary research centers on developing new vaccine strategies to combat Respiratory Syncytial Virus (RSV), a leading cause of hospitalization and death in young children worldwide. While monoclonal antibody treatments are accessible and affordable in countries like the U.S., they remain expensive and difficult to distribute in low-resource settings.
Infants under six months old are at the highest risk of severe RSV disease, and until recently, there were no vaccines available to protect them. In 2019 alone, RSV was estimated to cause 3.6 million hospitalizations and approximately 100,000 deaths in children under five years of age, with nearly half of these deaths occurring in infants younger than six months. Alarmingly, 97% of pediatric RSV-related deaths occur in low- and middle-income countries, where access to supportive medical care is limited (World Health Organization, 2025).
To address this urgent global health challenge, our lab explores next-generation immunization tools, like viral vectors, mRNA lipid nanoparticles and heterologous prime-boost regimens. We combine innovative computational modeling with cutting-edge experimental approaches to develop vaccines that induce long-lasting, broadly neutralizing antibody responses.
We use immunological shape space, a computational framework that models antibody-antigen interactions in a multidimensional landscape, to predict cross-reactivity and guide vaccine design by anticipating how the immune system responds to diverse antigens.
Beyond RSV, our work also targets other high-impact viruses, including Influenza, HIV, and SARS-CoV-2. We are always excited to welcome motivated students and researchers who are passionate about vaccine science, immunoengineering, and advancing global health. Whether you're drawn to hands-on lab work, computational biology, or translational research, there is a place for you in the Anderson Lab.

Christopher S. Anderson, Ph.D.
Principal Investigator
Publications
View All Publications- Single-cell analysis of lung epithelial cells reveals age and cell population-specific responses to SARS-CoV-2 infection in ciliated cells.; Clinical and experimental immunology. 2025 Jan 09.
- Short-Term Immunogenicity of Licensed Subunit RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) Compared to Community-Dwelling Older Adults.; Journal of the American Medical Directors Association. 2024 Sep 21.
- Association of disease severity and genetic variation during primary Respiratory Syncytial Virus infections.; BMC medical genomics; Vol 17(1), pp. 165. 2024 Jun 19.
- Generation and Functional Analysis of Defective Viral Genomes during SARS-CoV-2 Infection.; mBio. 2023 Apr 19.
Affiliations
Contact Us
Christopher Anderson Lab
601 Elmwood Ave/Box 689
Rochester, NY 14642